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Abstract
The advanced glycation end products, namely AGEs, contribute to long-termed complications of diabetes mellitus,
including macroangiopathy, where smooth muscle cells (SMC) proliferation stimulated by platelet-derived growth
factor (PDGF) isoforms and insulin-like growth factor-I (IGF-I) plays an important role. The objective of the present
study was to investigate the effect of an AGE-modified extracellular matrix protein on IGF-I induced SMC
proliferation and on the IGF-I-IGF binding protein 4 (IGFBP-4) axis under basal conditions and after stimulation with
PDGF-BB. IGF-I resulted in significantly higher thymidine incorporation in SMC seeded on AGE-modified fibronectin
(AGE-FN) in comparison to cells seeded on fibronectin (FN). This augmented proliferation could not be accounted
for by increased expression of IGF-IR, by decreased secretion of IGFBP-4, a binding protein that inhibits IGF-I
mitogenic effects or by increased IGF-IR autophosphorylation. PDGF-BB did not modulate IGF-IR and IGFBP-4 mRNA
expression in any of the substrata, however, this growth factor elicited opposite effects on the IGFBP-4 content in
the conditioned media, increasing it in cells plated on FN and diminishing it in cells plated on AGE-FN. These
findings suggest that one mechanism by which AGE-modified proteins is involved in the pathogenesis of diabetes-
associated atherosclerosis might be by increasing SMC susceptibility to IGF-I mitogenic effects.
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Background
Both type I and type II diabetes are powerful and independ-
ent risk factors for coronary artery disease, stroke, and per-
ipheral arterial disease [1,2]. Prolonged exposure to
hyperglycemia is recognized as the primary casual factor in
the pathogenesis of diabetic complications [3,4]. Hypergly-
cemia induces a large number of alterations in vascular tis-
sue that potentially promote accelerated atherosclerosis.
Glycation of proteins is an important biochemical mechan-
ism by which glucose mediates tissue damage, leading to the
generation of advanced glycation endproducts (AGEs) and
modifying the structure and function of several proteins,
such as those which comprise extracellular matrixes [5]. It
has been demonstrated that AGE formation alters some
functional properties of collagen [6], vitronectin [7], laminin
[8], and fibronectin (FN) [9], affecting their self-assembly
and their binding to each other. AGEs can also induce
synthesis and secretion of cytokines and growth factors after
binding to AGE receptors (RAGE) in different cell types [7].
Monocytes exposed to AGE-modified matrix release tumor
necrosis factor-α (TNF-α) [10], platelet-derived growth fac-
tor (PDGF) [11] and insulin-like growth factor-I (IGF-I)
[12]. In vascular smooth muscle cells (SMC) AGE-RAGE
interaction has been shown to activate cell signalling path-
ways linked to expression of inflammatory and prothrombo-
tic genes, such as ERK1/ERK2 kinases and NF-kB [13].
The SMC, which constitute the medial layer of arter-
ies, are normally in a differentiated contractile pheno-
type, but during the development of atherosclerotic
lesions, a subpopulation of SMC is converted to a syn-
thetic phenotype that is able to migrate and proliferate.
Extracellular matrix proteins actively participate in this
process, affecting SMC phenotype and modulating the
cellular response to growth-regulatory molecules [14].
FN, which is found in increased amounts in early ath-
erosclerotic plaques [15,16], can interact with cell sur-
face receptors and promote the conversion of SMC to
the synthetic state [17] and growth factors such as PDGF
and IGF-I will act, respectively, as competence and
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progression factors for cell replication [18], exerting syn-
ergistic effects on SMC proliferation [19]. IGF-I is
synthesized by vascular SMC where it is regulated by sev-
eral factors, such as PDGF [20-22]. The final biological
activity of IGF-I is determined by the number and affinity
of its receptors (IGF-IR) as well as by its binding proteins
(IGFBP) [23]. IGFBP-4, whose secretion is also modu-
lated by PDGF [22,24], is one of the predominant IGFBPs
produced by vascular SMC in culture, where it has an in-
hibitory effect on IGF-I- induced DNA synthesis [25].
The present study examined the effect of AGE-modified
FN on IGF-I induced SMC proliferation as well as on the
expression of IGF-IR and IGFBP-4 and their modulation
by PDGF-BB, in order to investigate pathways that could
be involved in diabetic macroangiopathy.
Materials and methods
This study was approved by the Institution’s Ethic Commit-
tee (Comitê de Ética em Pesquisa do Hospital das Clínicas
da Faculdade de Medicina da Universidade de São Paulo).
Materials
Fibronectin and other routine reagents were obtained
from Sigma Chemical Co. (St. Louis, MO), IGF-I and
Des (1–3) IGF-I were supplied by GroPep (Adelaide,
South Australia), PDGF-BB and all materials for cell cul-
ture were obtained from Life Technologies (Gaithersburg,
MD). Iodinated [125I] des (1–3) IGF-I, [125I] labelled
Protein A (100 mCi/mL) and ECL detection kit were
purchased from Amersham (Arlington Heights, IL). Anti-
body 1.2, a monoclonal antibody to the C-terminus of the
IGF-I receptor, was a kind gift from Dr. Kenneth Siddle
(Cambridge, UK). Anti-IGFBP-4 antibody was obtained
from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-
phosphotyrosine antibody (RC20H) conjugated to horse-
radish peroxidase was purchased from BD Transduction
Laboratories (Lexington, KY).
Preparation of AGE-modified FN
FN (2.5 mg) was incubated in phosphate-buffered saline
(PBS) (pH 7.4) with 500 mM D-glucose at 37°C in the
presence of protease inhibitors (1.5 mM phenylmethylsulfo-
nyl fluoride [PMSF], 0.5 mM EDTA) and antibiotics
(100 U/mL penicillin, 100 μg/mL streptomycin) for 6 weeks.
Control FN was incubated under the same conditions with-
out glucose. Unreacted sugar was removed by dialysis
against PBS. Characteristic fluorescence of the AGE com-
pound 2-(2-furoyl)-4(5)-(2-furanyl)-1 H-imidazole (FFI)
was observed at 440 nm after excitation at 375 nm [26]. FN
structural modification secondary to advanced glycation
was established by assessing bityrosine formation (400 nm
upon excitation at 325 nm) and tryptophan quenching
(334 nm upon excitation at 275 nm) [27] (Figure 1). Con-
trol and AGE-modified FN were evaluated on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) [28] using a 5% stacking gel and a 7.5% separating
gel and they exhibited indistinguishable electrophoretic
patterns, without any sign of degradation (data not shown).
Control and AGE-FN were plated at 4 μg/cm2 either onto
12-well tissue culture plates or onto 75 cm2 culture flasks
for 1 h at room temperature (RT). The plates were gently
rinsed three times with PBS before SMCs were allowed to
adhere.
Evaluation of SMC proliferation
An immortalized SMC line (AALTR-16) was kindly pro-
vided by Dr. J.K. McDougall (Fred Hutchinson Cancer Re-
search Center, Seattle, WA): human aortic SMCs were
infected with a retro viral vector containing the E6/E7 open
reading frame of human papilloma virus type 16. The E6
protein binds and promotes the degradation of the wild-type
p53 protein and the E7 protein forms an inactivating
complex with the product of the retinoblastoma tumor-
suppressor gene. These cells did not show any tumorigenic
activity in irradiated nude mice [29] and their
characterization by immunocytochemical studies and elec-
tronic microscopy demonstrated, respectively, expression of
alpha -smooth muscle actin and a synthetic phenotype, fea-
tured by a prominent endoplasmic reticulum. Lack of onco-
genic transformation was evaluated by serum dependent
assay (data not shown). The cells were maintained in
medium supplemented with 10% FCS, 1 mM l-glutamine,
100 U/mL penicillin and 100 μg/mL streptomycin at 37°C
in a humidified atmosphere of 95% air - 5% CO2, with
medium changes three times a week. Every five days, the
cells were harvested with a solution of 0.25% trypsin. To
study the effect of AGE-FN on SMC proliferation, cells were
seeded at 2×104 cells/cm2 into 96-well plates coated with
either FN or AGE-FN and were cultured in medium supple-
mented with 10% FCS until sub-confluence. After incuba-
tion with serum-free medium for 24-h, cells were incubated
for 24 h in serum-free medium (baseline) or in medium con-
taining IGF-I (the concentration of 100 ng/mL was used be-
cause a dose–response curve did not show a significant effect
of 10, 25 and 50 ng/mL of IGF-I on SMC proliferation
[data not shown]). After medium aspiration, fresh medium
containing 2 mCi/mL of [methyl-3 H] thymidine (Amer-
sham) was added for additional 4 h. The cells were rinsed
twice with ice-cold PBS, twice with ice-cold 5%
trichloroacetic acid, and twice with ice-cold 95% ethanol.
The cells were lysed in 0.3 mL of 1 N NaOH, neutralized
with 0.3 mL of 1 N HCI, and counted in a liquid scintilla-
tion counter. The results are expressed as the mean±SEM
of four independent experiments performed in duplicates.
IGF-I binding assay
SMC were seeded into 12-well plates coated with FN or
AGE-FN and were grown in medium supplemented with
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Figure 1 Characterization of AGE-modified FN (AGE-FN). Fluorescence of the AGE compound FFI observed at 440 nm after excitation at
375 nm (Panel A). Fibronectin (FN) structural modification secondary to advanced glycation was established by assessing bityrosine formation
(400 nm upon excitation at 325 nm) (Panel B) and tryptophan quenching (334 nm upon excitation at 275 nm) (Panel C).
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10% FCS until sub-confluence. After incubation with
serum-free medium for 24-h, the cells were washed with
1 mL of ligand binding buffer and incubated in 0.5 mL
of binding buffer containing 25,000 cpm of radiolabeled
material (125Des (1–3) IGF-I) and unlabeled competitor
(Des (1–3) IGF-I) in the following final concentrations:
0, 0.5, 1, 2, 4, 8, 16, 32 and 100 ng/mL as previously
described [30]. Total binding was designated as the
quantity of labeled ligand bound under these conditions.
Nonspecific binding was defined as the radioligand
bound in the presence of a 100-fold molar excess of un-
labeled ligand. Specific binding was calculated as the dif-
ference between total and nonspecific binding.125Des
(1–3) IGF-I binding kinetics were calculated using a
LIGAND computer program [31]. The results are
expressed as means ± SEM of three independent experi-
ments performed in duplicates.
IGF-IR protein content and autophosphorylation
IGF-IR protein levels were determined by immunoblot-
ting membranes containing cell lysates of SMC seeded
into 100-mm plates coated with FN or AGE-FN, grown
in medium supplemented with 10% FCS until sub-
confluence and synchronized by serum starvation for
24-h with antibody 1.2, a monoclonal antibody to the
C-terminus of the IGF-IR, as previously described [32].
Three independent experiments were performed. IGF-IR
autophosphorylation was analyzed by immunoblotting in
cell lysates (75 mg) with an antiphosphotyrosine antibody,
as previously described [32]; SMC seed into 100-mm
plates coated with FN or AGE-FN were grown in medium
supplemented with 10% FCS until sub-confluence
and after synchronization for 24-h, cells were incu-
bated either with or without IGF-I (100 ng/mL) for
1 min at 37°C. Three independent experiments were
performed.
IGFBP-4 detection
To study the effect of AGE-modified FN on IGFBP-4 se-
cretion, cells were plated at 3 × 104 cells/cm2 into
75 cm2 culture flasks coated with FN or AGE-FN, and
were grown in medium supplemented with 10% FCS
until sub-confluence. After being rinsed twice, they were
incubated with serum-free medium supplemented with
1 mM l-glutamine and antibiotics for 24-h. The medium
was then replaced with or without addition of PDGF-BB
(10 ng/mL) for 24-h. The conditioned medium was col-
lected and concentrated by ultrafiltration in 3 kDa MW
cut-off Centripep columns (Amicon Inc., Beverly, MA)
and protein was determined by the method described by
Bradford [33]. Identification of IGFBP-4 was performed
according to the anti-IGFBP-4 antibody manufacturer’s
Western Blot (WB) protocol (United Biotech, Inc.
Mountain View, CA). Briefly, after gel electrophoresis
and transference of proteins, the nitrocellulose mem-
brane was washed twice with water and blocked with
phosphate buffered saline (PBS) with 3% non-fat dry
milk for 20 min at RT. The membrane was then incu-
bated with a 1:2.000 dilution of antibody anti-human
IGFBP-4 (rabbit, polyclonal) in PBS 1% non-fat dry milk
at 4°C overnight. This was followed by two washes with
water and incubation for 2 h at RT with anti-rabbit im-
munoglobulin G (peroxidase-linked, Amersham) in PBS
1% non-fat dry milk. The membrane was washed twice
with water, once with PBS 0.05% Tween-20 and finally
four times with water. A chemiluminescent peroxidase
substrate (ECL) was applied for 1 min and the mem-
brane was exposed briefly to autoradiographic film. The
densities of the bands were determined by scanning
densitometry. Three independent experiments were
performed.
Evaluation of IGF-IR and IGFBP-4 mRNA abundance
To study the effect of AGE-modified FN on IGF-IR and
IGFBP-4 mRNA content, total RNA from cells from the
previous experiment was prepared using TRIzolW re-
agent (Invitrogen, Carlsbad, CA) accordingly to standard
protocols provided by the manufacturer. RNase protec-
tion assay was performed as previously described [34]
using the following probes: (I) IGF-IR probe, which is a
379 bp fragment of human IGF-IR cDNA cloned into a
pGEM3 vetor [35], (II) IGFBP-4 probe, which is a 505-
bp fragment of human IGFBP-4 cDNA cloned into a
pBSK+ vector [36] and (III) 18S RNA riboprobe, which
served as an internal control. Three independent experi-
ments were performed.
Statistical analysis
Data were analyzed by non-parametric tests. Mann–
Whitney test was employed for two unpaired groups and
and Kruskal-Wallis test when three or more groups were
analyzed. Statistical significance was set to p< 0.05. All
statistical analyses were performed by JMP Version 5.01
(SAS Institute Inc. Cary, NC, USA).
Results
SMC proliferation
As shown in Figure 2, IGF-I elicited an increment sig-
nificantly higher (P< 0.05) in thymidine incorporation
in SMC grown on AGE-FN than in cells grown on FN
demonstrating the stimulatory effect of AGE on SMC
proliferation in the presence of IGF-I. No differences in
thymidine incorporation were observed between SMC
coated in FN and AGE-FN in the absence of IGF-I.
IGF-I binding and IGF-IR autophosphorylation
In order to investigate if AGE-FN promotes increased
SMC proliferation by augmenting IGF-IR number and/
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or affinity, an IGF-I binding assay was performed with
Des(1–3) IGF-I, a truncated form of IGF-I (lacking the
N-terminal tripeptide Gly-Pro-Glu) that has much
reduced IGFBP affinity compared with natural IGF-I
[37]. Thus the use of this analog avoids falsely elevated
IGF-IR binding sites, which may occur with any binding
of IGF-I radioligand to IGFBPs. IGF-binding curves fit-
ted to one binding site (Figure 3). The receptor numbers
per cell were not different between SMC plated on FN
and on AGE-FN (1.33 × 104 in both conditions), neither
were the relative affinities for IGF-IR (Kd of 6.64 × 10−11
and 6.31 × 10−11, respectively) (P> 0.05). Also, the evalu-
ation of IGF-IR by Western blot did not show any sig-
nificant difference between the abundance of this
protein on SMC grown on FN and AGE-FN (P> 0.05)
(Figure 4). Since changes in IGF-IR number and affinity
could not explain increased cell proliferation stimulated by
IGF-I in presence of AGE-FN, autophosphorylation of the
IGF-IR was examined by Western blot with an anti-
phosphotyrosine antibody. IGF-I stimulated autophosphor-
ylation of SMC seeded on both FN and AGE-FN did
not consistently differ between the two experimental
conditions (P> 0.05) (Figure 5).
IGFBP-4 content
To additionally investigate if a decrease in IGFBP-4, a
binding protein that inhibits IGF-I mitogenic effects, was
involved in the increased SMC proliferation determined by
AGE-FN, a Western blotting employing an antibody anti-
human IGFBP-4 was performed. As shown in Figure 6,
after 24 h of incubation in serum-free media, the content
of IGFBP-4 in the conditioned media of SMC grown on
AGE-FN was similar to the observed in the conditioned
media of cells seeded on FN (P> 0.05), however, treatment
with 10 ng/mL of PDGF-BB for 24 h evoked opposite
effects on the IGFBP-4 content, augmenting (range from
40–60%) this binding protein in the conditioned media
from SMC grown on FN (as observed in cells maintained
in plastic substratum [data not shown] and as described in
previous studies [22,24]) and decreasing (range from 28–
46%) it in the conditioned media of SMC cultivated in
AGE-FN (P< 0.05). This result suggests that the inter-
action of SMC with AGE-FN modifies the dynamic of
IGFBP-4 secretion induced by PDGF-BB, resulting in ele-
vation of local free IGF-I, which may contribute to SMC
proliferation.
NF-EGANF
Figure 3 Scatchard plots of Des (1–3)IGF-I binding sites in vascular smooth muscle cells inoculated on fibronectin (FN) or AGE-
modified FN (AGE-FN). The abscissa shows bound 125Des (1–3)IGF-I; the ordinate indicates the ratio of bound (B) Des (1–3)IGF-I to free (F) Des
(1–3)IGF-I. A plot representative of three independent experiments is shown.
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Figure 2 Effect of the presence (+) or absence (−) of IGF-I
(100 ng/mL) on cell proliferation in vascular smooth muscle
cells inoculated on fibronectin (FN) and on AGE-modified
fibronectin (AGE-FN). The results are expressed as mean± SEM of
four independent experiments performed in duplicates.
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IGF-IR and IGFBP-4 mRNA abundance
We next examined the effect of AGE-FN on IGF-IR and
IGFBP-4 expression before and after treatment with
PDGF-BB, given the known influence of PDGF isoforms
on the IGF-I axis in SMC [22,24]. IGF-I expression was
not evaluated because preliminary experiments have
demonstrated low expression levels of this growth factor
in the studied cell line (data not shown). IGF-IR mRNA
and IGFBP-4 mRNA abundances were not affected by
AGE-FN in comparison to the abundance observed in
cells grown on FN substrata after 24 h, and treatment with
PDGF-BB had no effect on the content of IGF-IR and
IGFBP-4 mRNAs in relation to untreated cells in both
substrata (P> 0.05) (Figure 7), suggesting that the modu-
lation of IGBBP-4 secretion observed after PDGF-BB
treatment is probably due to post-transcriptional events.
Discussion
There is now a considerable body of evidence supporting
an important role for AGEs and its receptors in the dia-
betic vascular dysfunction [38], such as the suppression
of accelerated atherosclerotic lesion development by
Figure 4 Western blot analysis of IGF-IR in smooth muscle cells
inoculated on fibronectin (FN) and on AGE-modified FN
(AGE-FN). Lysates of cells grown in medium supplemented with
10% FCS until sub-confluence and synchronized by serum starvation
for 24-h were analysed using antibody 1.2, a monoclonal antibody
to the C-terminus of the IGF-IR. A blot representative of three
independent experiments is shown. O.D., optical density.
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Figure 5 IGF-I stimulation of tyrosine phosphorylation in
smooth muscle cells inoculated on fibronectin (FN) and on
AGE-modified fibronectin (AGE-FN). Lysates of sub-confluent cells
exposed (+) or not (−) to IGF-I (100 ng/mL) were analyzed by Western
blotting using a antiphosphotyrosine antibody. A blot representative of
three independent experiments is shown. O.D., optical density.
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Figure 6 Western blot analysis of IGFBP-4 in conditioned media
of SMC grown on fibronectin (FN) or AGE-modified FN (AGE-
FN). Sub-confluent cells were pre-incubated in serum-free media for
24-h prior to a 24-h exposure to serum-free media (Control) or to
20 ng/mL PDGF-BB (PDGF-BB). A blot representative of three
independent experiments is shown. O.D., optical density.
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interruption of AGE-RAGE interaction in diabetic
rodents [39]. Our finding of increased IGF-I induced
human aortic SMC proliferation in presence of AGE-FN
suggests a participation of this growth factor in the
atherogenic process related to protein glycation. Given
the findings of Chisalita et al. [40], who reported that
the expression of IGF-IR is five-fold higher compared to
the expression of insulin receptor in human aortic SMC,
it is probable that the proliferative effect of IGF-I is
being exerted through IGF-IR, although we had not
found increased phosphorylation of IGF-IR.
Previous studies have already demonstrated a stimulatory
effect of AGE on the growth of rat [41], rabbit [42], porcine
[43] and human [44] vascular SMC. Seki et al. [45], who
also reported a proliferative effect of AGE on rat SMC, did
not detect any change in the phosphorylation of
PDGF receptor. In common with the present study,
SMC were chronically maintained in AGE and were
acutely stimulated with the growth factor in the
phosphorylation experiment. Thus, these two studies
suggest that chronic exposure of SMC to AGE did
not modify the phosphorylation status of PDGF and
IGF receptors, although it positively affected cell pro-
liferation. On the other hand, activation of p42 mito-
gen-activated protein kinase (MAPK) [42] and of
p21ras/MAP kinase pathway [46] were described in
SMC acutely exposed to AGE, demonstrating the
direct activation of these transduction pathways by
AGE-RAGE interactions.
Human vascular SMCs synthesize and secrete IGFBP-2,
-4, -5 and −6. Their expression is regulated by many fac-
tors, including PDGF, and they are important determi-
nants of SMC responses to IGF-I [47] inhibiting (IGFBP-
4) or potentiating (IGFBP-5) its mitogenic effect [48]. We
evaluated IGFBP-4, the most abundant binding protein
secreted by human SMC and found that AGE-FN modi-
fies its modulation by PDGF-BB, decreasing IGFBP-4 pro-
duction in comparison to FN substratum, in which
PDGF-BB elicits an increased secretion. Since IGFBP-4 is
known to inhibit IGF-I action, the reduction of IGFBP-4
secretion induced by PDGF-BB could result in augmented
availability of IGF-I. It is well known that the functions of
IGFBPs on vascular SMC are regulated by post-transla-
tional processing such as proteolysis [47]. In the case of
IGFBP-4, the metalloproteinase pregnancy-associated
plasma protein A (PAPP-A), expressed in vascular SMC
[49], is recognized as the main protease. It remains to be
elucidated if, in the presence of AGE-FN, PDGF-BB could
induce PAPP-A expression, increasing IGFBP-4 proteoly-
sis and eventually decreasing the abundance of this bind-
ing protein. This is an interesting possibility in light of
previous works demonstrating that PAPP-A expression is
stimulated by TNF-α in human coronary SMC [50] and in
human fibroblasts [51] and that, in the latter cell type,
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Figure 7 RNase protection assay analysis of IGF-IR (Panel A) and IGFBP-4 (Panel B) mRNA of SMC grown on fibronectin (FN) or AGE-
modified FN (AGE-FN). Sub-confluent cells were pre-incubated in serum-free media for 24-h prior to a 24-h exposure to serum-free media
(Control) or to 20 ng/mL PDGF-BB (PDGF-BB). Twenty micrograms of total RNA were cohybridized with hIGF-IR or hIGFBP-4 and 18S RNA
riboprobes. A blot representative of three independent experiments is shown. O.D., optical density.
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NFκB was identified as the primary mediator of TNF-α
stimulated PAPP-A gene expression [52]. Both TNF-α [10]
and NFκB [13,45] are stimulated after cellular exposure to
AGE-modified proteins.
Since we did not perform experiments evaluating autop-
hosphorylation of PDGF-BB receptor, we cannot rule out
that a decrease in PDGF-BB receptor signaling is taking
place in presence of AGE-FN, which could partially ex-
plain an absence of PDGF-BB effect increasing IGFBP-4
in the conditioned media. A previous study of Cantero
et al. found that dicarbonyl compounds, highly reactive
compounds that react with proteins to form AGEs, modi-
fied PDGF-induced PDGFRβ-phosphorylation by inhibit-
ing its intrinsic tyrosine kinase activity [53].
Conclusions
This study suggests that AGE-modified FN modulates
SMC’s response to IGF-I and PDGF-BB, both present in
the vascular wall, potentially contributing to the patho-
genesis of diabetes associated atherosclerosis by increasing
SMC susceptibility to IGF-I mitogenic effects.
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